StockStory.org on MSN
IART Q3 Deep Dive: Supply Chain Progress, Product Relaunches, and Margin Pressures Shape Outlook
Medical device company Integra LifeSciences (NASDAQ:IART) in Q3 CY2025, but sales rose 5.6% year on year to $402.1 million.
Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In today's volatile business landscape, building a resilient supply chain is crucial for ...
Analysts are holding their oil price forecasts largely unchanged as rising OPEC+ output targets and lacklustre demand offset ...
The 2008 financial crash ripped a giant hole in the incomes and wealth of Americans, limiting their ability to afford everything from big-ticket purchases like cars to their rent. The government ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback